Newsroom

Oncology

Late-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer

Significantly lower infusion-related reactions seen with subcutaneous amivantamab compared with intravenous administration in new Phase 2 data

June 3, 2024

Oncology

CARVYKTI^® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma

73 percent reduction in risk of disease progression or death seen with CARVYKTI^® in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy¹

June 3, 2024

Oncology

Johnson & Johnson advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA

PALOMA-3 presentation of subcutaneous amivantamab and lazertinib selected to showcase cutting-edge approaches in lung cancer during prestigious “Best of ASCO” program

New data showcase first- and -best-in-class, complementary multiple myeloma therapies, including DARZALEX^®(daratumumab), CARVYKTI^®(ciltacabtagene autoleucel; cilta-cel), TECVAYLI^®(teclistamab-cqyv) and TALVEY^®(talquetamab-tgvs)

May 23, 2024

Oncology

Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery

May 7, 2024

Oncology

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively

May 7, 2024

Oncology

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress

May 6, 2024

United States

Oncology

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non–muscle-invasive bladder cancer

May 6, 2024

Oncology

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

April 22, 2024

Belgium

Oncology

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

April 6, 2024

United States

Oncology

RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson’s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer

March 18, 2024

Newsroom

Press Releases

Discover J&J

Medicines & therapies

Medical devices & technology

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

About us

You are now leaving innovativemedicine.jnj.com

Key links

Get in touch

Search Results

No Results

Recently Viewed

Newsroom

Press Releases

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com